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Abstract
Background: An interesting field of research in genomics and proteomics is to compare the overlap between the
transcriptome and the proteome. Recently, the tools to analyse gene and protein expression on a whole-genome
scale have been improved, including the availability of the new generation sequencing instruments and high-
throughput antibody-based methods to analyze the presence and localization of proteins. In this study, we used
massive transcriptome sequencing (RNA-seq) to investigate the transcriptome of a human osteosarcoma cell line
and compared the expression levels with in situ protein data obtained in-situ from antibody-based
immunohistochemistry (IHC) and immunofluorescence microscopy (IF).
Results: A large-scale analysis based on 2749 genes was performed, corresponding to approximately 13% of the
protein coding genes in the human genome. We found the presence of both RNA and proteins to a large fraction
of the analyzed genes with 60% of the analyzed human genes detected by all three methods. Only 34 genes
(1.2%) were not detected on the transcriptional or protein level with any method. Our data suggest that the
majority of the human genes are expressed at detectable transcript or protein levels in this cell line. Since the
reliability of antibodies depends on possible cross-reactivity, we compared the RNA and protein data using
antibodies with different reliability scores based on various criteria, including Western blot analysis. Gene products
detected in all three platforms generally have good antibody validation scores, while those detected only by
antibodies, but not by RNA sequencing, generally consist of more low-scoring antibodies.
Conclusion: This suggests that some antibodies are staining the cells in an unspecific manner, and that
assessment of transcript presence by RNA-seq can provide guidance for validation of the corresponding antibodies.
Background
Several studies have attempted to compare protein and
transcript expression levels to investigate the central
dogma of the cell, i.e. the relation between DNA, RNA
and protein content in a cell [1-8]. Microarrays have
been the prevalent platform to measure the abundance
of transcripts in a sample, although other technologies
such as SAGE have also been employed. The corre-
sponding protein abundance estimates have frequently
been obtained through mass spectrometry or protein
arrays. The resulting correlation coefficients in these
comparative analyses have varied significantly, from 0.3
to 0.9, comparing 10 s of genes up to 1000 s of genes.
Sub-groups representing functionally different Gene
Ontology groups could, however, display both higher
and lower correlations depending on their role in the
cellular machinery [7].
To improve an estimate of correlation between RNA
and protein molecules a more unbiased approach com-
bined with a digital gene expression profile is needed.
Massive DNA sequencing technology offers a new possi-
bility to achieve a comprehensive and quantitative view
of all genes being transcribed in a sample [9-11]. Here,
we compare global IHC and IF protein expression in a
human osteosarcoma cell line, U-2 OS (from the
Human Protein Atlas program, HPA)[12], with massive
DNA sequencing of the corresponding transcriptome
(RNA-seq).
Results
The aim of this study was to compare the transcriptome of
human U-2 OS cells with presence of the corresponding
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close to saturation by performing massive SOLiD DNA
sequencing [Additional file 1: Supplemental figure S1]. In
total, approximately 15 million high quality 35-bp reads
were obtained and mapped onto the human reference gen-
ome (hg18) and quantitative measures were computed on
a per gene basis. Analysis of the transcription pattern
demonstrated that the majority of all Ensembl genes
(73.4%; 15536/21146 genes) were expressed in U-2 OS,
i.e., a transcript being represented by at least one uniquely
mapped read. The frequency distribution is presented in
the additional information [Additional file 1: Supplemental
figure S2].
To create a comparative protein expression set, a non-
redundant collection of antibodies and genes was
assembled from the Human Protein Atlas [12]. In the
initial collection of data, a high degree of protein pre-
sence was observed for both IHC and IF, demonstrating
expressed proteins for 88.7% and 73.6% of all genes ana-
lyzed, respectively (Table 1). In the following analysis,
all antibodies with protein expression data from both
IHC and IF in the U-2 OS cell line were used. For the
genes with more than one antibody directed towards the
gene product, the best scoring IF antibody was selected
according to a standard validation scheme [Additional
file 1: Supplemental table S1]. The assembled non-
redundant set of antibodies was then used to collect
corresponding immunohistochemistry and immuno-
fluorescence information from U-2 OS, yielding the
HPA subset. The HPA subset consists of 2749 Ensembl
genes (with corresponding 2749 antibodies) that all have
protein presence/absence information from both IHC
and IF experiments (in the U2-OS cell line). Figure 1
shows the obtained data for gene NDUFS4 as an exam-
ple of the input data for the three included platforms,
IHC (A), IF (B) and RNA-seq (C).
Protein distribution and overlap with transcriptional data
Using the transcriptome sequencing strategy, we detect
transcripts for 85.3% (2123+222) of the genes in the
H P As u b s e t( T a b l e1 ) .Al a r g eo v e r l a pi ne x p r e s s i o ni s
obvious comparing RNA-seq and the immunological
assays. Figure 2 compares presence of proteins and tran-
scripts, and it demonstrates that out of the HPA subset,
RNA-seq detects 87.1% (2123/2123+315) of the IHC-
detected proteins, and 87.2% (1771/1771+260) of the IF-
detected proteins. These numbers are higher than what
is expected by chance; a chi-square test results in p-
values of 3.4 × 10
-13 and 2.6 × 10
-6 for IHC and IF,
respectively. This supports a strong association between
RNA and protein expression. The fact that approxi-
mately 13% of all detected proteins does not have a
detectable transcript can indicate several different phe-
nomena: (i) Some genes are very lowly expressed as
transcripts, but efficiently translated into stable protein
products or (ii) Some antibodies are cross-reactive,
yielding false positive protein detection.
Interestingly, 9.4% (222/2123+222) of the genes in the
HPA subset that were detectedo nt h et r a n s c r i p tl e v e l
are not detected on the protein level. For IF, this num-
ber is 24.4% (574/1771+574). It is not clear if this is
caused by a subset of genes that are transcribed but not
translated, or if this is due to a limited sensitivity in the
Table 1 Study summary
Method Number of
antibodies
Number of genes
analyzed
Percentage of total number of
genes analyzed
Number of genes present of
common subset
Percentage present of
common subset
RNA-seq na na na 2345 85.3%
IHC 5329 4380 21.2% 2439 88.7%
IF 3626 3268 15.9% 2023 73.6%
Common
subset
2749 2749 13.3% na na
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Figure 1 Overview of the data types used. (A) Images acquired
from IHC were automatically processed and annotated. (B) Images
from IF were manually annotated with staining intensity and a
validation score. (C) For RNA-sequencing, reads mapping uniquely
to exons were counted and an RPKM value was calculated for each
gene.
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higher for IF than IHC indicates that unspecific anti-
body-protein interaction in IHC in combination with a
group of transcripts that do not undergo translation is
the major contributor to this affect, since the sensitivity
of IF is generally higher than that of IHC (see below).
Comparison over three technology platforms
For a more in-depth analysis, we investigated the
expressed genes in a combined analysis of IHC, IF and
R N As e q u e n c i n go ft h eH P As u b s e t( 2 7 4 9g e n e s ) .W e
show that 60.1% (1651 genes) of all investigated genes
are detected by all platforms (Figure 3A) and only 1.2%
(34 genes) was not detected by any platform. If only one
of the two proteins detection platforms is required to
call presence on the protein level (in the case of one of
them producing a false positive call), only 3.2% - 5.2% of
all genes are not detected on the transcript or RNA
level. Interestingly, 71% (1651+205)/(110+472+1651+205
+55+120) of proteins detected by either IHC or IF were
detected by both methods. In total, IHC detects more
proteins than IF (2438 vs. 2031). The higher number of
detected genes likely indicates a higher degree of false
positives, since genes detected by IF and RNA-seq are
more lowly expressed than genes detected by IHC and
RNA-seq (Figure 3B, see below).
Since RNA-seq provides quantitative measures of gene
expression levels, we investigated transcript levels for the
genes in the subgroups defined in Figure 3A, where this
was possible (Figure 3B). This showed that the groups ‘C’
and ‘BC’ (detected in RNA-seq only and detected in IF
and RNA-seq positive, respectively) were expressed at
significantly lower levels than all genes combined (Kol-
m o g o r o v - S m i r n o v( K S )t e s t ,p=3 . 8×1 0
-4 a n dp=4×
10
-4, respectively). This indicates that IF has a higher sen-
sitivity to detect transcriptionally low expressed genes
than IHC.
Next, we investigated the overlap between RNA and
protein expression using the quantitative RPKM [10]
values as a measure of transcript abundance. This measure
is calculated by counting all reads that map to the exons of
a gene and dividing by the length of the gene and total
number of reads and is an expression value for each gene.
The HPA subset was binned in 25 transcriptional levels,
ranging from the top 5% of the bottom 5% expressed
genes, as well as two transcriptional levels: the upper 50%
and lower 50% expressed genes. Table 2 shows a 95%
overlap between the upper 50% genes and protein pre-
sence based on IHC expression. For the lower 50%, this
number drops to 82% and for IF, this overlap is 80% and
68% for the upper and lower intervals, respectively. Inter-
estingly, for the smaller bins, this effect is very similar: The
overlap is high (98% for IHC, 86% for IF) for the top 5%
and remains relatively similar across the top 50% [Addi-
tional file 1: Supplemental figure S3]. Furthermore, we
chose the subset of antibodies that had the highest valida-
tion score (supportive staining) in Western blot [Addi-
tional file 1: Supplemental table S1], and as expected, this
yielded a slightly higher degree of overlap for both IHC
and IF (Table 2) suggesting that some of the antibodies
with a low validation score might be false positives.
Gene Set Enrichment Analysis
DAVID [13,14] is a tool that performs gene set enrich-
ment analysis for several different categories (GO,
KEGG, protein domains etc) and has the option to
group similar categories into functional groups based on
similarity. When the HPA subset (2749 genes) was ana-
lyzed for enrichment of gene categories against a back-
ground of all protein coding genes using DAVID some
Gene Ontology categories emerged as over-represented.
These include development, apoptosis, proteins related
to direct protein sequencing, the cytoplasm and protein
binding (data not shown).
A
IHC +
89 315 2123 222 12787
(3.2%) (11.5%) (77.2%) (8.1%)
IHC RNA−seq
IHC -
B
IF +
144 260 1771 574 12787
(5.2%) (9.5%) (64.4%) (20.9%)
IF RNA−seq
IF -
Figure 2 (A) Overlap of IHC data with RNA data. In IHC, 88.7% of
the investigated genes are present. (B) As in (A), but overlap
between IF and RNA-sequencing. In IF, 73.9% of the investigated
genes are called present. The ‘present overlaps’ between IHC and
RNA-sequencing and IF and RNA-seq are 77.2% and 64.4%,
respectively.
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Page 3 of 9Thus, since the HPA subset is somewhat biased from
a gene category perspective, further gene set analysis of
t h es u b g r o u p sw a sd o n ew i t ht h eH P As u b s e ta sb a c k -
ground. We noticed that for genes in the ABC group
(detected by all platforms, Figure 3A), certain themes
were enriched. Two category sub-clusters were signifi-
cantly over-represented; intracellular proteins and
nuclear proteins (Table 3). From a technical perspective,
these proteins are located within the cells (or even
within the nucleus) and are therefore equally well
detected using either IHC or IF. As a contrast, in the
BC group (IHC-, IF+, RNA+) we find that extracellular
proteins are significantly enriched (a group of proteins
usually not detected by IF). Given the higher sensitivity
of IF, we might speculate that these are proteins des-
tined for export that still reside within the cells, and
thus are present at very low levels.
In the AB group (IHC+, IF+, RNA-), we notice that
proteins related to glycosylation are significantly
enriched. The apparent lack of correlation between
AB
C
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1651
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RNA-seq
Group IHC IF RNA-seq
A+- -
B- + -
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Figure 3 (A) Venn diagram of presence flags for the three platforms (A = IHC, B = IF, C = RNA-seq). 60.1% of all genes investigated are
present in all platforms. Only 34 genes (1.2%) are absent in all platforms. (B) Cumulative transcription density curves for the categories where
RNA-sequencing data are available (C, AB, BC, ABC). A left-shifted curve contains a larger fraction of low transcribed genes. The category C (blue
line) (RNA-seq only) contains genes with lower transcription than the full HPA subset (solid black line) (KS-test, one-sided, p = 3.8 × 10
-7). Also,
genes in BC (green line) (RNA-seq positive, IF positive, IHC negative) have generally a lower level of transcription than the HPA subset (KS-test,
one-sided, p = 4 × 10
-5). This is likely due to a higher sensitivity in IF than IHC. Interestingly, genes in the HPA subset display generally higher
transcription levels (KS-test, one-sided, p < 2.2 × 10
-16) than all protein coding genes (dashed black line).
Table 2 Overlap between RNA and protein based on RNA expression bins
Percent of present genes
All antibodies Antibodies with supportive Western blot
Fraction of genes based on transcript level IHC IF IHC IF
Top 50% 95.2% 79.9% 96.6% 83.1%
Bottom 50% 82.1% 67.8% 83.4% 73.2%
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fully understood and requires further analysis to eluci-
date (Figure 4A, see below).
Western blot and IF validation score analysis
The Western blots performed within the HPA program
are manually investigated and assigned a validation
score based on the number of detected bands, approxi-
mate size of the bands etc [Additional file 1: Supple-
mental table S1] using a standardized protein lysate
panel. We analyzed these scores for all groups defined
in Figure 3A. We observe that antibodies raised against
genes in the A group (positive only in IHC) or the AB
group (IHC+, IF+, RNA-) generally contain more low-
scoring antibodies (KS-test, p = 1.6 × 10
-4 and KS-boot-
s t r a pt e s t ,p=2×1 0
-3) (Figure 4A). This suggests that
some of these antibodies are staining the cells in an
unspecific manner (false positives) and the RNA data
can thus provide guidance for the validation of the
corresponding antibodies. Western blot data was not
available for our particular U-2 OS cell line analysed in
this study, so a direct expression comparison between
WB and other methods was not possible.
For IF images in the HPA program, a validation score
is added after manual investigation. Comparative analy-
sis of these scores could only be done for groups with
staining according to IF, since a validation score of 7 is
used to define absence. In the ABC group (present in all
platforms), the fraction of antibodies receiving a suppor-
tive score [Additional file 1: Supplemental table S1]
is about three times higher than that in the B group
(present only in IF) and is confirmed significant
(KS-bootstrap test, 2 × 10
-3).
Discussion
A quantitative comparison of the transcriptome and the
proteome in a cell (or tissue) is instrumental in deci-
phering fundamental regulatory pathways and mechan-
isms. The relationship between these two sets of
biomolecules also has wide implications for the identifi-
cation of new biomarkers and classifiers in the treat-
ment of disease. Previous efforts to compare the
transcript and protein abundance, at single or multiple
gene levels, have demonstrated a great variation in out-
come, attributed to both biological and technical issues
[1-8]. From a technical perspective, transcriptome
Table 3 DAVID enrichment for certain categories
Group Enriched theme p-value
ABC Nucleus 1, 03 × 10
-14
Intracellular 8,22 × 10
-23
AB Glycosylation site:N-linked (GlcNAc...) 9,97 × 10
-6
BC Extracellular region 4,39 × 10
-7
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Figure 4 (A) Western blot data for the groups defined in figure 3A. The groups A and AB generally contain a larger fraction of low-scoring
antibodies. (B) IF Reliability scores for the same subgroups. The fraction of antibodies with a supportive staining in the ABC group is about three
times higher that in the B group (p < 2 × 10
-3).
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seq, which provides a digital and comparably unbiased
profile of all genes transcribed in a cell. We show that
almost 75% of all genes are represented by one or more
transcripts, which is in line with other recent studies
[10]. We also demonstrate that lowly expressed genes
are less likely to be identified at the protein level.
The proteome has in most cases been represented by
indirect methods such as arrays or by mass spectometry
of a solubilized proteome. Here, we present a large-scale
comparison of in-situ protein abundance in cells with
the transcription levels provided by RNA-seq. The pro-
teins are assessed by antibodies targeting the proteome,
and the presence of a particular protein species is visua-
lized by immunohistochemistry and immunofluores-
cence microscopy, from which an abundance is
estimated. These are two semi-quantitative methods and
we therefore performed the comparison at the level of
presense/absense.
For 87% of all detected proteins, we were able to detect
a corresponding transcript. For the remaining 13% of all
detected proteins (where we found no transcript), it can
indicate several different phenomena: 1) Some genes are
very lowly expressed as transcripts, but efficiently trans-
lated into stable protein products or 2) Some antibodies
are cross-reactive, yielding false positive protein detec-
tion. Both of there effected would yield result where pro-
teins are detected but the transcript is not.
We observe approximately 2/3 overlap between the
RNA and its corresponding protein species, irrespective
of method. Even if one of the two methods for genera-
tion of protein expression data is considered false, only
3.2% - 5.2% of all investigated genes are not detected on
the protein or transcript level. Overall, immunohisto-
chemistry identifies slightly more proteins than immu-
nofluorescence, and we suggest that this elevated
detection is in part due to false IHC positives, as indi-
cated by the fact that IF demonstrates higher sensitivity
for the lowly expressed genes (Figure 3B). Interestingly,
the transcriptome-negative but IF- and IHC-positive
group (8%), contained an over-representaion of genes
related to glycosylation and needs to be confirmed with
alternative methods such as mass spectrometry and RT-
PCR. The group of genes detected by RNA-seq and IF
but not IHC is significantly enriched for secreted pro-
teins. Of 69 genes in this GO category, 33 are present in
this group (p = 4.4 × 10
-7).
Conclustions
Our study demonstrates that RNA-seq is useful as a
validation tool for the HPA program. In the case of pre-
viously uncharacterized proteins or conflicting data
between protein array, Western blot, IHC and IF, we
could use both the presence/absence call and the
quantitative estimation of RNA molecules to decide on
the quality of data. Indeed, presence of RNA does indi-
cate that a corresponding protein can be expected in the
analyzed sample. Furthermore, RNA-seq has been
shown to efficiently identify splice variants [15], and this
may also be used to discriminate between multiple anti-
bodies directed towards different parts of the target
protein.
We used the quantitative estimation of RNA mole-
cules to show that the highest expressed genes are more
likely represented by a corresponding protein. For the
50% highest expressed genes we detect the correspond-
ing protein in more than 80% (IF) or 95% (IHC) of the
cases. These numbers reveal a signficantly closer rela-
tionship between the presence of RNA and protein than
what has been seen in previous studies. We believe that
our data indicate that both RNA and proteins are
expressed to a more significant extent than previously
anticipated and that this means that cells are regulated
at the level of protein abundance rather than on mere
presence/absence. The next step in our understanding
of the cell machinery will therefore require more sensi-
tive and quantitative measures of proteins.
Methods
Cell cultivation
The osteosarcoma cell line U-2 OS (ATCC-LGC Pro-
mochem, Borås, Sweden) was cultivated in a 5% CO2
environment at 37°C in McCoy’s 5A media, as suggested
by the provider, with the addition of 10% Fetal Bovine
Serum (FBS) and an antibiotic/antimycotic solution
(both from Invitrogen).
RNA sample preparation and cDNA synthesis
Cells were harvested and RNA was extracted using the
RNeasy extraction kit as instructed by the manufacturer
(Qiagen) and quality-assessed using the RNA nano kit
on a BioAnalyzer 2100 (Agilent). The BioAnalyzer can
interpret the generated data and score it with a RNA
I n t e g r i t yN u m b e r( R I N )r a n g i n gf r o m1( v e r yd e g r a d e d )
to 10 (no degradation). 10 μgo fh i g h - q u a l i t y( R I N> 9 . 5 )
total RNA was used as input material for depletion of
ribosomal fragments using RiboMinus (Invitrogen). 250
ng ribosome-depleted RNA was adjusted to 4.5 μli n
nuclease-free water and fragmented in 95°C for 20 min-
utes, after which it was immediately transferred to ice.
1 μl of biotinylated tagged random hexamers (Biotin-
TEG-CTTTCCTCTCTATGGGCAGTCGGTGATNNN
NNN, 1 pmol/μl, Operon) was added and the mixture
was denatured at 70°C for 10 minutes and on ice for
2 minutes. During incubation, a cDNA-synthesis master
mix consisting of (per sample) 6 μl5 xF i r s t - s t r a n db u f -
fer (Invitrogen), 3 μl 0.1 M DTT (Invitrogen), 7.5 μl
dNTP mixture (2 mM/dNTP) and 6.5 μl nuclease-free
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was added to the denatured RNA:hexamer mixture
together with 2 μl SuperScript III (Invitrogen) on ice.
The first strand cDNA synthesis reaction was incubated
at 20°C for 10 minutes followed by 37°C for 10 minutes
and 42°C for 45 minutes. First-strand cDNA was puri-
fied by addition of 70 μl nuclease-free water using a
MinElute spin column following the manufacture’s
instructions (Qiagen). Elution was carried out twice,
each in 10 μl of EB-buffer, with a 180° rotation of the
column in the centrifuge between the elutions. A second
strand synthesis master mix was assembled on ice. This
consisted of (per sample) 79 μl nuclease-free water, 30
μl 5x second-strand buffer (Invitrogen), 15 μld N T P
mixture (2 mM/dNTP), 1 μl1 0U / μl E. coli DNA Ligase
(Invitrogen), 4 μl1 0U / μlE .c o l iD N Ap o l y m e r a s eI
(Invitrogen) and 1 μl2U / μl RNase H (Invitrogen). Of
this, 130 μlw a sa d d e dt ot h e≈18 μl eluate containing
the RNA:cDNA hybrid. The reaction was incubated at
16°C for 2 hours, after which 1.5 μl3U / μlT 4D N A
Polymerase (New England Biolabs) was added, and the
reaction was incubated for 5 more minutes at 16°C.
Enrichment and SOLiD DNA sequencing
20 μl of Streptavidin Dynabeads M-270 (Invitrogen)
were washed in 50 μl1 ×B W - b u f f e r( 2 0m MT r i s ,
2 mM EDTA, 1 M NaCl) and pelletized using a MPC-6
magnetic particle concentrator (Invitrogen). To the pel-
let, the 150-μl second-strand syntheis reaction and 150
2× BW buffer were added, mixed by gentle vortexing
and incubated on gentle rotation using a RotaMix
(Elmi) at room temperature (≈22°C) for 15 minutes. The
bead-DNA complex was then washed three times in
100 μl sterile deionised water and pelletized. A PNK-
master mix consisting of (per reaction) 15 μl sterile deio-
nised water, 2 μl PNK buffer (Invitrogen), 2 μl1 0m M
ATP and 1 μl1 0U / μl PNK was assembled on ice and 20
μl was added to the pelletized beads and mixed by pipet-
ting. The reaction was incubated at room temperature
for 15 minutes. To create a blunt-ended dsDNA adapter
sequence suitable for ligation to the beads, a mixture
consisting of 440 μls t e r i l ed e i o n i s e dw a t e r ,5μl 100
pmol/μl RDV primer (AACTGCCCCGGGTTCCT-
CATTCTCT, MWG-Biotech), 5 μl1 0 0p m o l / μla R D V
primer (AGAGAATGAGGAACCCGGGGCAGTT,
MWG-Biotech) and 50 μl PNK buffer (Invitrogen) was
assembled and incubated at 95°C for 3 minutes and
allowed to cool to room temperature on a lab bench for
30 minutes. A ligation master mix consisting of 4 μl5 ×
Ligase buffer (Invitrogen), 1 μl1p m o l / μl RDV:aRDV
duplex, 14 μl sterile deionised water and 1 μl3U / μlT 4
DNA Ligase was assembled on ice, added to the pelle-
tized beads and mixed by pipetting. The reaction was
incubated for 16 hours on a RotaMix at room
temperature. The ligation reaction was washed three
times in sterile deionised water and the beads were resus-
pended in 20 μl of sterile deionised water.
An amplification master mix was assembled, consist-
ing of 5 μl 5× HF buffer (Finnzymes), 10 μl sterile deio-
nised water, 5 μl dNTP mix (2 mM/dNTP), 1 μl1 0
pmol/μl RDV primer (AACTGCCCCGGGTTCCT-
CATTCTCT, MWG-Biotech), 1 μl1 0p m o l / μl
LAmpFDV (CCACTACGCCTCCGCTTTCCTCTC-
TATGGGCAGTCGGTGAT, MWG-Biotech) and 1 μl
2U / μl Phusion polymerase (Finnzymes). 23 μl amplifi-
cation master mix and 2 μl beads were mixed denatured
at 95°C for 30 seconds and cycled as follows: 30 seconds
at 95°C, 30 seconds at 55°C, 30 seconds at 72°C for
16 cycles. After a final extension at 72°C for 10 minutes,
the PCR product was purified using a MinElute column,
following the manufacturers instructions with the
elution step as described earlier.
The PCR product was subjected to emPCR and
SOLiD sequencing following the manufacturers instruc-
tions (Life Technologies/Applied Biosystems). Fifteen
million 35-base pair reads passed quality filters including
filtering against adaptors.
Mapping of DNA reads and defining the transcriptome
The reads were mapped to the human genome (hg18)
following the manufacturers instructions. A read was
considered to be unique if is mapped to a single location
with N mismatches and nowhere with N+1 or N+2 mis-
matches (i.e. a clear zone of 2). In total, 6 442 847 reads
aligned uniquely to EnsEMBL genes. Only unique reads
with a maximum of three mismatches were used to cal-
culate expression values. A gene was considered present
if at least one read fell entirely inside an exon of the
gene. Raw sequence data has been deposited to the
NCBI Short Read Archive with accession number
SRA023713.1.
Production of Antibodies
The antibodies used in this study have been generated
within the Human Protein Atlas program http://www.
proteinatlas.org [16]. For each application using the gen-
erated antibodies, a standard set of categories has been
established, and these are grouped into three main
validation scores: (i) supportive, (ii) uncertain, or
(iii) non-supportive [Additional file 1: Supplemental
table S1] [18].
Western blot analysis
Prior to immunohistochemistry and immunofluores-
cence the HPA antibodies were analysed by Western
blot as previously described [16]. All membranes were
incubated with the primary antibodies diluted 1:500.
The secondary HRP-conjugated antibody (Swine Anti-
Klevebring et al. BMC Genomics 2010, 11:684
http://www.biomedcentral.com/1471-2164/11/684
Page 7 of 9Rabbit Immunoglobulin/HRP, DakoCytomation) was
diluted 1:3000 and detection was carried out using a
CCD-camera. Seven categories (1-87) for the Western
blot validation have been proposed in which three
(grade 1-3) are supportive, two (grade 4-5) are uncertain,
and two (grade 6-7) are non-supportive.
Immunohistochemical analysis
Immunohistochemistry was performed on cell microar-
rays (CMA) where U-2 OS cells were represented, as
previously described [18]. In brief, cells were harvested,
fixed in formalin and dispersed into agarose. After histo-
processing and paraffin embedding of the cell pellets
resulting in donor blocks, duplicate 0.6 mm punches
were sampled and put into one recipient CMA. 4 micron
sections were subsequently cut and immunohistochemi-
cally stained using an Autostainer Plus instrument
(Dako, Glostrup, Denmark). An automated slide-scanner
system, Scanscope T2 (Aperio Technology, Vista, CA,
USA) was used to image the stained sections, resulting
in digital images representing separated cell spots from
the CMA.
The images were analyzed by an automated image
analysis software, TMAx (Beecher instruments, Sun
Praire, WI, USA), which identifies cells, measures the
immunostaining and counts the fraction of stained cells,
all according to processing logic previously described
[19]. The measured staining intensity was further cate-
gorized into a IHC graded scale (negative, weak, moder-
ate and strong). Here, the analyzed protein was
considered “absent” when the staining intensity score
was negative and “present” when the staining intensity
score was weak, moderate or strong.
Immunofluorescence microscopy
Immunofluorescent stainings were performed as pre-
viously described [20]. Briefly, cells were seeded in
96-well glass bottom plates, fixed with paraformaldehyde
and permeabilized with Triton X-100 before immuno-
fluorescently stained. The entire procedure was auto-
mated using a pipetting robot. Besides the HPA
antibody staining, organelle markers for microtubules,
endoplasmic reticulum and nuclei were included. Image
acquisition was performed manually using a LSM 510
Meta confocal laser-scanning microscope equipped with
a 63x oil-immersion objective (Carl Zeiss GmbH, Jena,
Germany). For each sample, two representative four-
channel images were acquired. The laser power and
detector gain were adjusted for each sample to obtain as
good signal to noise ratios as possible and to use the
entire dynamic range of the detector.
The images were visually inspected and annotated in
terms of staining intensity and subcellular localization.
A graded scale (negative, weak, moderate and strong)
was used to categorize the staining intensity based on
the used laser power and detector gain. For each anti-
body a validation score was set based on how well the
observed subcellular localization agreed with informa-
tion in the UniProt database. The IF validation scores
consist of a nine-graded scale that can be merged into
three main categories: supportive, uncertain or not
supportive [Additional file 1: Supplemental table S1].
Here, the analyzed protein was considered “absent”
when the validation score was 7 (no staining, see
[Additional file 1: Supplemental table S1]) and “pre-
sent” otherwise.
Additional material
Additional file 1: Supporting tables and figures. Supporting tables
and figures.
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